BR9809694A - Processo e composição para administração de taxanos oralmente a pacientes humanos - Google Patents
Processo e composição para administração de taxanos oralmente a pacientes humanosInfo
- Publication number
- BR9809694A BR9809694A BR9809694-0A BR9809694A BR9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A BR 9809694 A BR9809694 A BR 9809694A
- Authority
- BR
- Brazil
- Prior art keywords
- taxane
- human patients
- administered
- oral
- orally
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 2
- 108010036949 Cyclosporine Proteins 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 238000009101 premedication Methods 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: <B>"PROCESSO E COMPOSIçãO PARA ADMINISTRAçãO DE TAXANOS ORALMENTE A PACIENTES HUMANOS"<D>. Agentes antineoplásticos de taxano que até aqui exibiram biodisponibilidade oral fraca ou não existente são administrados oralmente a pacientes humanos sofrendo de estados de doença em resposta a taxano e são tornados suficientemente biodisponíveis para atingir os níveis sang³íneos terapêuticos. Em uma modalidade preferida, o taxano, preferencialmente paclitaxel, é co-administrado ao paciente com um agente de melhoramento oral ciclosporina, preferencialmente ciclosporina A. Por um processo preferido, uma dose de melhorador oral é administrada a aproximadamente 0,5-72 horas antes do taxano e uma segunda dose do melhorador é administrada imediatamente antes, junto com ou imediatamente depois do taxano. é também fornecido um processo para tratar pacientes humanos sofrendo de estados de doença em resposta a taxano, assim como um processo para fornecer tal tratamento enquanto previne ou reduz a hipersensibilidade e as reações alérgicas sem a necessidade de pré-medicação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86351397A | 1997-05-27 | 1997-05-27 | |
| PCT/US1998/007776 WO1998053811A1 (en) | 1997-05-27 | 1998-04-22 | Method and compositions for administering taxanes orally to human patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9809694A true BR9809694A (pt) | 2000-10-03 |
Family
ID=25341241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9809694-0A BR9809694A (pt) | 1997-05-27 | 1998-04-22 | Processo e composição para administração de taxanos oralmente a pacientes humanos |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0994706B1 (pt) |
| JP (1) | JP2002500667A (pt) |
| KR (1) | KR100615783B1 (pt) |
| CN (2) | CN1550231A (pt) |
| AR (1) | AR012731A1 (pt) |
| AT (1) | ATE308365T1 (pt) |
| AU (1) | AU7130098A (pt) |
| BR (1) | BR9809694A (pt) |
| CA (1) | CA2290446C (pt) |
| CZ (1) | CZ9904244A3 (pt) |
| DE (1) | DE69832173T2 (pt) |
| DK (1) | DK0994706T3 (pt) |
| ES (1) | ES2247690T3 (pt) |
| HU (1) | HUP0003546A3 (pt) |
| IL (2) | IL132992A0 (pt) |
| NO (1) | NO995812L (pt) |
| PL (1) | PL337064A1 (pt) |
| RU (1) | RU2205005C2 (pt) |
| SK (1) | SK157599A3 (pt) |
| UA (1) | UA74767C2 (pt) |
| WO (1) | WO1998053811A1 (pt) |
| ZA (1) | ZA984268B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| ATE219363T1 (de) * | 1997-06-20 | 2002-07-15 | Baker Norton Pharma | Lösliche prodrugs von paclitaxel |
| GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| WO2000069390A2 (en) | 1999-05-17 | 2000-11-23 | Cancer Research Ventures Limited | Compositions for improving bioavailability of orally administered drugs |
| RU2236226C2 (ru) * | 1999-06-18 | 2004-09-20 | Бейкер Нортон Фармасьютикалз, Инк. | Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением |
| PL354777A1 (en) * | 1999-10-27 | 2004-02-23 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| KR20020013174A (ko) * | 2000-08-11 | 2002-02-20 | 민경윤 | 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물 |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| MXPA03006404A (es) * | 2001-01-18 | 2004-12-02 | Upjohn Co | Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada. |
| UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
| EP1623706A3 (en) * | 2001-02-28 | 2006-02-22 | Bristol-Myers Squibb Company | Metronomic dosing of taxanes for inhibiting tumor growth |
| US7063977B2 (en) | 2001-08-21 | 2006-06-20 | Bristol-Myers Squibb Company | Enzymatic resolution of t-butyl taxane derivatives |
| CA2569139A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Lapatinib with letrozole for use in a treatment of breast cancer |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CN102803234A (zh) * | 2009-06-02 | 2012-11-28 | 霓坎制药有限责任公司 | 用于治疗疾病的人甲酰基肽受体的拮抗作用 |
| EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| BR112023018826A2 (pt) * | 2021-03-17 | 2024-03-12 | Dompe Farm Spa | Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| JPH06504772A (ja) * | 1990-12-18 | 1994-06-02 | ザ ウエルカム ファウンデーション リミテッド | 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤 |
| DE69220037T2 (de) * | 1991-01-11 | 1997-11-06 | Laboratoires Glaxo S.A., Paris | Acridinderivate |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| JP2986550B2 (ja) * | 1994-07-26 | 1999-12-06 | インデナ・ソシエタ・ペル・アチオニ | 抗腫瘍活性を有する半合成タキサン |
| TW354293B (en) * | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
| US5916566A (en) * | 1995-06-07 | 1999-06-29 | Avmax, Inc. | Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| WO1997027855A1 (en) * | 1996-01-31 | 1997-08-07 | Bristol-Myers Squibb Company | A method of making pharmaceutically active taxanes orally bioavailable |
| CA2258556A1 (en) * | 1996-06-17 | 1997-12-24 | Julian Stanley Kroin | Drug resistance and multidrug resistance modulators |
| GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| KR100661879B1 (ko) * | 1998-04-01 | 2006-12-27 | 스키에파마 캐나다 인코포레이티드 | 항암 조성물 |
-
1998
- 1998-04-22 DK DK98918361T patent/DK0994706T3/da active
- 1998-04-22 RU RU99128033/14A patent/RU2205005C2/ru not_active IP Right Cessation
- 1998-04-22 JP JP50066399A patent/JP2002500667A/ja active Pending
- 1998-04-22 IL IL13299298A patent/IL132992A0/xx active IP Right Grant
- 1998-04-22 UA UA99116450A patent/UA74767C2/uk unknown
- 1998-04-22 CN CNA2004100304785A patent/CN1550231A/zh active Pending
- 1998-04-22 CN CN98806440A patent/CN1261275A/zh active Pending
- 1998-04-22 AU AU71300/98A patent/AU7130098A/en not_active Abandoned
- 1998-04-22 CZ CZ19994244A patent/CZ9904244A3/cs unknown
- 1998-04-22 BR BR9809694-0A patent/BR9809694A/pt not_active IP Right Cessation
- 1998-04-22 CA CA002290446A patent/CA2290446C/en not_active Expired - Fee Related
- 1998-04-22 KR KR1019997011000A patent/KR100615783B1/ko not_active Expired - Fee Related
- 1998-04-22 AT AT98918361T patent/ATE308365T1/de not_active IP Right Cessation
- 1998-04-22 WO PCT/US1998/007776 patent/WO1998053811A1/en not_active Ceased
- 1998-04-22 SK SK1575-99A patent/SK157599A3/sk unknown
- 1998-04-22 PL PL98337064A patent/PL337064A1/xx unknown
- 1998-04-22 EP EP98918361A patent/EP0994706B1/en not_active Expired - Lifetime
- 1998-04-22 ES ES98918361T patent/ES2247690T3/es not_active Expired - Lifetime
- 1998-04-22 DE DE69832173T patent/DE69832173T2/de not_active Expired - Fee Related
- 1998-04-22 HU HU0003546A patent/HUP0003546A3/hu unknown
- 1998-05-20 ZA ZA984268A patent/ZA984268B/xx unknown
- 1998-05-21 AR ARP980102356A patent/AR012731A1/es unknown
-
1999
- 1999-11-17 IL IL132992A patent/IL132992A/en not_active IP Right Cessation
- 1999-11-26 NO NO995812A patent/NO995812L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR012731A1 (es) | 2000-11-08 |
| UA74767C2 (en) | 2006-02-15 |
| DK0994706T3 (da) | 2006-03-06 |
| DE69832173D1 (de) | 2005-12-08 |
| EP0994706A1 (en) | 2000-04-26 |
| ES2247690T3 (es) | 2006-03-01 |
| CZ9904244A3 (cs) | 2001-10-17 |
| DE69832173T2 (de) | 2006-08-03 |
| KR100615783B1 (ko) | 2006-08-25 |
| WO1998053811A1 (en) | 1998-12-03 |
| NO995812D0 (no) | 1999-11-26 |
| KR20010013025A (ko) | 2001-02-26 |
| CN1550231A (zh) | 2004-12-01 |
| ZA984268B (en) | 1999-06-23 |
| CA2290446C (en) | 2008-01-29 |
| ATE308365T1 (de) | 2005-11-15 |
| HUP0003546A2 (hu) | 2002-11-28 |
| CN1261275A (zh) | 2000-07-26 |
| CA2290446A1 (en) | 1998-12-03 |
| AU7130098A (en) | 1998-12-30 |
| SK157599A3 (en) | 2002-10-08 |
| NO995812L (no) | 2000-01-25 |
| IL132992A0 (en) | 2001-03-19 |
| IL132992A (en) | 2006-08-20 |
| HK1026637A1 (en) | 2000-12-22 |
| EP0994706B1 (en) | 2005-11-02 |
| HUP0003546A3 (en) | 2002-12-28 |
| PL337064A1 (en) | 2000-07-31 |
| RU2205005C2 (ru) | 2003-05-27 |
| EP0994706A4 (en) | 2001-05-16 |
| JP2002500667A (ja) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
| Picus et al. | Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
| BR0015149A (pt) | Método e composições para administração de taxanos oralmente a pacientes humanos | |
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| WO1999040883A3 (en) | Compositions and methods for the treatment of cystic fibrosis | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
| WO1999056666A8 (en) | The treatment of sexual dysfunction in certain patient groups | |
| CA2519789A1 (en) | Aplidine for multiple myeloma treatment | |
| KR940013503A (ko) | 동맥경화증의 예방 또는 치료용 약제학적 조성물 | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| RU2182006C2 (ru) | Способ лечения ревматоидного артрита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1769 DE 20041130 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007. |